You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
格隆匯港股聚焦(02.17)︱ 君實生物抗TIGIT單抗注射液臨試申請獲FDA批准;萬國國際礦業年度純利預增五成
格隆匯 02-17 22:31

【業績預吿】

萬國國際礦業(03939.HK)年度純利預增五成

寶威控股(00024.HK)預計2020財年實現經營盈利約860萬港元

TRUE PARTNER(08657.HK)預計年度由虧轉盈2338萬至2857萬港元

【營運數據】

國泰航空(00293.HK)1月載客量跌99% 載貨量跌28.3%

TRUE PARTNER(08657.HK)1月末資產管理規模約16億美元

【股本重組】

普匯中金國際(00997.HK):股本重組將於2月19日生效

【投資與運營】

君實生物(01877.HK):抗TIGIT單抗注射液臨牀試驗申請獲得FDA批准

君實生物(01877.HK):XPO1抑制劑JS110獲得藥物臨牀試驗申請受理通知書

翰森製藥(03692.HK)與SCYNEXIS訂立許可協議

貝康醫療-B(02170.HK):與PGT-SR試劑盒相關的重要專利已於國家知識產權局註冊

伯明翰體育(02309.HK)澄清:球會於20-21賽季的預測虧損為任軒冬的個人觀點

【回購註銷】

復星國際(00656.HK)2月17日耗資2461.13萬港元回購200萬股

中國旺旺(00151.HK)2月17日耗資291.4萬港元回購50萬股

DYNAM JAPAN(06889.HK)2月17日耗資83.60萬港元回購10.64萬股

東瑞製藥(02348.HK)2月17日耗資25.8萬港元回購18.4萬股

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account